|
|
|
|
|||||
|
|
|
We recently compiled a list of the 15 High Growth Mid-Cap Stocks to Buy. Veracyte, Inc. is one of the high growth stocks on our list.
TheFly reported on January 5 that Guggenheim analyst Subbu Nambi raised the price target for VCYT to $50 from $45, maintaining a Buy rating on the stock. The firm updated its models and forecasts for companies in the Diagnostics and Life Sciences Tools sector based on insights gained from recent management meetings.
Separately, on January 11, Veracyte, Inc. (NASDAQ:VCYT) released preliminary full-year 2025 results and 2026 guidance. It forecasts $570 million to $582 million in sales in 2026, which is higher than the consensus of roughly $565 million and shows sustained growth momentum.
Veracyte, Inc. (NASDAQ:VCYT) is a genomic diagnostics company that develops tests to improve diagnosis and treatment decisions for thyroid, lung, and other cancers, as well as autoimmune diseases, aiming to reduce unnecessary procedures and enhance patient care through precision medicine.
While we acknowledge the potential of VCYT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.
Disclosure: None.
| 5 hours | |
| 6 hours | |
| 13 hours | |
| Jan-21 | |
| Jan-21 | |
| Jan-19 | |
| Jan-19 | |
| Jan-14 | |
| Jan-13 | |
| Jan-12 | |
| Jan-11 | |
| Jan-08 | |
| Jan-07 | |
| Jan-05 | |
| Dec-31 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite